Pooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC)

被引：0

作者：

Tripathy, D. ^{[1
]}

Hortobagyi, G. N. ^{[1
]}

Chan, A. ^{[2
]}

Im, S-A. ^{[3
]}

Chia, S. ^{[4
]}

Yardley, D. ^{[5
]}

Esteva, F. J. ^{[6
]}

Hurvitz, S. A. ^{[7
]}

Ridolfi, A. ^{[8
]}

Slamon, D. ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

[2] Curtin Univ, Breast Canc Res Ctr BCRC WA, Sch Med, Nedlands, WA, Australia

[3] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea

[4] Univ British Columbia, Dept Med, Vancouver, BC, Canada

[5] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[6] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[7] Univ Calif Los Angeles, UCLA Hematol Oncol Santa Monica, Los Angeles, CA USA

[8] Novartis Pharmaceut, Rueil Malmaison, France

[9] Univ Calif Los Angeles, Davide Geffen Sch Med, Los Angeles, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

155P

引用

页码：49 / +

页数：2